Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab as first-line treatment in patients with advanced colorectal carcinoma

Next Previous
X
Search
Trial Profile

Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab as first-line treatment in patients with advanced colorectal carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin
  • Indications Carcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CAIRO-3; CAIRO3

    • Most Recent Events

    • 12 Sep 2017 Results of impact of sarcopenia on dose-limiting toxicities in patients from CAIRO3 study presented at the 42nd European Society for Medical Oncology Congress
    • 01 Sep 2017 Results of post-hoc subgroup analysis, published in the Annals of Oncology.
    • 06 Jun 2017 Results assessing skeletal muscle index loss in 416 CAIRO3 patients presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top